A multicenter, 3-arm, open-label, phase iia clinical trial to evaluate safety and efficacy of tanibirumab (vegfr2 mab), in patients with recurrent gbm assessed with k-trans and initial area under the gadolinium concentration-time curve (iaugc) Conference Paper uri icon

authors

  • Cher, Lawrence
  • Nowak, Anna
  • Iatropoulos, Georgios
  • Lee, Weon Sup
  • Lee, Seon Young
  • Shim, Sang Ryeol
  • Yoo, Jin San

publication date

  • 2017